Real Time Touch



new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)




Real Time Touch

Similar
Filing Names

Medimmune Llc
Medimmune Llc_20131212
  

Medimmune Llc patents

Recent patent applications related to Medimmune Llc. Medimmune Llc is listed as an Agent/Assignee. Note: Medimmune Llc may have other listings under different names/spellings. We're not affiliated with Medimmune Llc, we're just tracking patents.

ARCHIVE: New 2017 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "M" | Medimmune Llc-related inventors




Date Medimmune Llc patents (updated weekly) - BOOKMARK this page
09/21/17Molecules with altered neonate fc receptor binding having enhanced therapeutic and diagnostic properties
07/20/17Cell culture methods and media comprising n-acetylcysteine
06/29/17Multi-specific anti-pseudomonas psl and pcrv binding molecules and uses thereof
06/29/17Antibody scaffold for homogenous conjugation
06/22/17Antibody formulation
05/25/17Method for purifying active polypeptides or immunoconjugates
05/11/17Treatment of polybacterial infections
05/11/17Alpha-v beta-8 antibodies
05/04/17Interferon alpha-induced pharmacodynamic markers and uses thereof
04/27/17Multispecific and multivalent binding proteins and uses thereof
04/20/17Single-use, self destructing shield for syringe needle
04/20/17Methods for treating chronic obstructive pulmonary disease using benralizumab
03/30/17Compositions and methods for identifying b cell malignancies responsive to b cell depleting therapy
03/16/17Mrka polypeptides, antibodies, and uses thereof
02/23/17Stable anti-ifnar1 formulation
01/19/17Compositions and methods for modulating and redirecting immune responses
12/22/16Anti-pcsk9-glp-1 fusions and methods for use
12/15/16Dipeptidyl peptidase-4 (dpp4/cd26) as a peripheral biomarker of il-13 activation in asthmatic lung
11/24/16Tubulysin derivatives
11/24/16Rsv-specific antibodies and functional parts thereof
11/10/16Compositions and methods for treating sarcoma
10/27/16Novel assay to detect human periostin
10/06/16Swine influenza hemagglutinin and neuraminidase variants
09/08/16Neutralizing anti-influenza a antibodies and uses thereof
09/08/16Methods of treating s. aureus-associated diseases
09/01/16Antibody purification
08/18/16Binding molecules specific for her3 and uses thereof
08/18/16Binding molecules specific for her3 and uses thereof
08/11/16Recombinant respiratory syncytial virus (rsv) and vaccines
08/04/16Methods of treatment with angiopoietin-2 antibodies
07/28/16Protein formulation
07/14/16Assay to detect human dpp-4
06/09/16Binding molecules specific for her3 and uses thereof
06/09/16Stabilized liquid anti-rsv antibody formulations
05/26/16Vaccine composition and use
05/26/16Humanized anti-cd19 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
05/19/16Humanized anti-ox40 antibodies and uses thereof
05/12/16Antibodies and other molecules that bind b7-h1 and pd-1
04/21/16Purification of recombinantly produced polypeptides
04/07/16Anti-b7-h5 antibodies and their uses
03/24/16Separation of recombinant polyclonal antibody multimers with minimal separation of monomers
02/25/16Methods of producing influenza vaccine compositions
02/11/16Influenza hemagglutinin variants and uses therefor
02/11/16Palivizumab epitope-based virus-like particles
01/28/16Ox40l fusion proteins and uses thereof
01/28/16Type i interferon diagnostic
01/28/16Recombinant polypeptide production
01/21/16Engineered fc regions for site-specific conjugation
12/17/15Methods of using ion exchange chromatography to control levels of high mannose glycoforms
11/26/15Methods of producing immunoconjugates
11/19/15Antibodies against and methods for producing vaccines for respiratory syncytial virus
11/19/15Anti-b7-h1 and anti-ctla-4 antibodies for treating non-small cell lung cancer
10/15/15Tubulysin derivatives
10/15/15Antibodies to s. aureus surface determinants
10/08/15Method of isolating synagis(r) in the absence of benzonase
10/08/15Combination therapies using anti-pseudomonas psl and pcrv binding molecules
09/03/15Antibody formulation
08/27/15Stable, low viscosity antibody formulation
08/06/15Methods of treating pediatric acute lymphoblastic leukemia with an anti-cd22 immunotoxin
07/02/15Regimens for treatments using anti-igf antibodies
06/18/15Cancer stem cells and methods of using the same
06/04/15Antibodies with decreased deamidation profiles
05/07/15Molecules with reduced effector function and extended half-lives, compositions, and uses thereof
05/07/15Antibodies against and methods for producing vaccines for respiratory syncytial virus
04/30/15Stable, aqueous antibody formulations
Patent Packs
04/23/15Antibody production methods
04/16/15Methods for treating chronic obstructive pulmonary disease using benralizumab
04/16/15Ctla-4 variants
03/26/15Stabilized liquid anti-rsv antibody formulations
03/12/15Antibody formulation
02/19/15Devices having thermochromic response indicators
02/12/15Methods for reducing exacerbation rates of asthma using benralizumab
02/12/15Methods for increasing forced expiratory volume in asthmatics using benralizumab
02/12/15Methods for improving asthma symptoms using benralizumab
02/12/15Interferon alpha-induced pharmacodynamic markers and uses thereof
02/12/15Methods of treatment with angiopoietin-2 antibodies
01/22/15Combination therapies using anti-pseudomonas psl and pcrv binding molecules
12/25/14Molecules with extended half-lives, compositions and uses thereof
12/11/14Binding molecules specific for her3 and uses thereof
10/09/14Human anti il-6 antibodies with extended in vivo half-life and their use in treatment of oncology, autoimmune diseases and inflammatory diseases
Patent Packs
10/09/14Methods for processing coagulation factors
09/04/14Hsa-related compositions and methods of use
08/28/14Dosing regimens for treatment of cea-expressing cancers
08/28/14Influenza hemagglutinin and neuraminidase variants
08/14/14Anti-pseudomonas psl binding molecules and uses thereof
08/07/14Multi plasmid system for the production of influenza virus
07/24/14Targeted binding agents directed to dll4 and uses thereof
07/17/14Influenza b viruses having alterations in the hemaglutinin polypeptide
06/19/14Molecules with extended half-lives and uses thereof
06/19/14Modulation of antibody effector function by hinge domain engineering
05/29/14Hsa-related compositions and methods of use
05/22/14Protein scaffolds
05/15/14Multi plasmid system for the production of influenza virus
05/08/14Refrigerator-temperature stable influenza vaccine compositions
04/03/14Human-murine chimeric antibodies against respiratory syncytial virus
03/20/14Influenza hemagglutinin and neuraminidase variants
03/13/14Antibodies that specifically bind staphylococcus aureus alpha toxin and methods of use
02/27/14Stabilized liquid anti-rsv antibody formulations
02/13/14Melanoma treatments
01/23/14Influenza hemagglutinin and neuraminidase variants
01/23/14Expression of soluble viral fusion glycoproteins in mammalian cells
12/12/13Combination therapy for b cell lymphomas
12/12/13Antibody scaffold for homogenous conjugation
12/12/13Regimens for treatments using anti-igf antibodies
10/17/13Methods for processing inclusion bodies
09/19/13Influenza hemagglutinin and neuraminidase variants
09/05/13Cell display of antibody libraries
08/08/13Method for purifying active polypeptides or immunoconjugates
07/25/13Influenza hemagglutinin and neuraminidase variants
07/25/13Preservation of bioactive materials by freeze dried foam
Social Network Patent Pack
07/25/13Methods of producing inflenza vaccine compositions
07/25/13Multi plasmid system for the production of influenza virus
06/20/13Influenza hemagglutinin and neuraminidase variants
06/06/13Anti-icos antibodies and their use in treatment of oncology, transplantation and autoimmune disease
05/09/13Swine influenza hemagglutinin variants
05/09/13Humanized anti-cd19 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
05/02/13Optimized degenerative muscle disease diagnostics and treatments
04/25/13Multi plasmid system for the production of influenza virus
04/18/13Trail r2-specific multimeric scaffolds
04/11/13Methods of use related to xerostomia
Patent Packs
03/14/13Non-splicing variants of gp350/220
03/14/13Preparation of negative-stranded rna viruses by electroporation
02/28/13Molecules with extended half-lives, compositions and uses thereof
02/28/13Mdck cell lines supporting viral growth to high titers and bioreactor process using the same
02/07/13Methods and compositions for detecting and treating cea-expressing cancers
12/27/12Methods of diagnosing and treating pulmonary diseases or disorders
12/27/12Targeted binding agents directed to sonic hedgehog homolog and uses thereof
12/27/12Methods and compositions for expressing negative-sense viral rna in canine cells
12/06/12Recombinant rsv virus expression systems and vaccines
11/29/12Influenza hemagglutinin and neuraminidase variants
11/15/12Multi plasmid system for the production of influenza virus
11/08/12Refrigerator-temperature stable influenza vaccine compositions
11/08/12Quantification of ir-a and ir-b for tumor classification
10/18/12Topical methods of treating rsv infections and related conditions
10/18/12Compositions and methods involving respiratory syncytial virus subgroup b strain 9320
10/11/12Methods for cultivating cells, propagating and purifying viruses
10/04/12Type 1 inteferon diagnostic
09/27/12Swine influenza hemagglutinin variants
08/30/12Auto-antibody markers of autoimmune disease
08/23/12Engineered fc regions for site-specific conjugation
08/02/12Multi plasmids system for the production of influenza virus
07/12/12Methods of treating pediatric acute lymphoblastic leukemia with an anti-cd22 immunotoxin
06/21/12Antibodies against and methods for producing vaccines for respiratory syncytial virus
06/07/12Method of identifying membrane ig specific antibodies and use thereof for targeting immunoglobulin-producing precursor cells
05/31/12Ultra high affinity neutralizing antibodies
05/17/12Modulators of epha2 and ephrina1 for the treatment of fibrosis-related disease
05/03/12Recombinant il-9 antibodies and uses thereof
03/22/12Methods of administering / dosing anti-rsv antibodies for prophylaxis and treatment
03/08/12Non-splicing variants of gp350/220
02/23/12Stabilized anti-respiratory syncytial virus (rsv) antibody formulations
Patent Packs
02/23/12Recombinant parainfluenza virus vaccine comprising heterologous antigens derived from respiratory syncytial virus
02/23/12Modulation of antibody effector function by hinge domain engineering
02/16/12Stabilized liquid anti-rsv antibody formulations
02/09/12Influenza hemagglutinin and neuraminidase variants
02/09/12Influenza hemagglutinin and neuraminidase variants
01/12/12Antibody formulations
01/12/12Preservation of bioactive materials by spray drying
12/22/11Molecules with extended half-lives, compositions and uses thereof
11/24/11High affinity antibodies against hmgb1 and methods of use thereof
11/17/11Methods of preventing or treating t cell malignancies by administering anti-cd2 antagonists
11/17/11Methods of preventing or treating inflammatory or autoimmune disorders by administering cd2 antagonists in combination with other prophylactic or therapeutic agents
10/27/11Disease markers and uses thereof
10/20/11Antibody formulation
10/20/11Methods to molecularly characterize circulating tumor cells
07/28/11Humanized anti-cd22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
07/07/11Methods of use related to xerostomia
06/30/11Methods of preventing and treating rsv infections and related conditions
06/02/11Antibodies with decreased deamidation profiles
05/26/11Swine influenza hemagglutinin variants
04/21/11Methods of administering/dosing cd2 antagonists for the prevention and treatment of autoimmune disorders or inflammatory diseases
Social Network Patent Pack
04/21/11Crystals and structure of human igg fc variant
03/31/11Antibody library display by yeast cell plasma membrane
03/31/11Hinge domain engineering
03/24/11Influenza hemagglutinin and neuraminidase variants
03/10/11Anti-ifnar1 antibodies with reduced fc ligand affinity
03/10/11Non-splicing variants of gp350/220
03/03/11Serum-free virus propagation platform for a virus vaccine candidate
02/24/11Methods and compositions for expressing negative-sense viral rna in canine cells
02/03/11Stabilized liquid anti-rsv antibody formulations
01/06/11Influenza hemagglutinin and neuraminidase variants
12/30/10Cell display of antibody libraries
12/23/10Influenza b viruses having alterations in the hemaglutinin polypeptide
12/02/10Anti-il-9 antibody formulations and uses thereof
11/25/10Preservation of bioactive materials by freeze dried foam
11/25/10Protein scaffolds
11/04/10Epha2 monoclonal antibodies and methods of use thereof
11/04/10Antibodies against and methods for producing vaccines for respiratory syncytial virus
10/21/10Il-9 in fibrotic and inflammatory disease
10/21/10Auto-antibody markers of autoimmune disease
10/21/10Ultra high affinity neutralizing antibodies
Social Network Patent Pack
10/14/10Il-33 in inflammatory disease
10/14/10Interferon alpha-induced pharmacodynamic markers
10/07/10Protein formulations
09/23/10Antibodies against mammalian metapneumovirus
09/16/10Multispecific epitope binding proteins and uses thereof
08/26/10Framework-shuffling of antibodies
08/19/10Antibody formulation
08/12/10Eph receptor fc variants with enhanced antibody dependent cell-mediated cytotoxicity activity
08/12/10Methods and compositions for expressing negative-sense viral rna in canine cells
08/05/10Targeted binding agents directed to cd105 and uses thereof
07/29/10Functional mutations in respiratory syncytial virus
07/22/10Influencing viral lipid constituents
07/01/10Use of epha4 and modulator of epha4 for diagnosis, treatment and prevention of cancer
06/10/10Molecules with reduced half-lives, compositions and uses thereof
06/10/10Interferon alpha-induced pharmacodynamic markers
06/10/10Methods of treating systemic lupus erythematosus
06/10/10Increasing the production of recombinant antibodies in mammalian cells by site-directed mutagenesis
05/13/10Recombinant parainfluenza virus expression systems and vaccines
05/06/10Non-tumorigenic mdck cell line for propagating viruses
05/06/10Mdck cells lines supporting viral growth to high titers and bioreactor process using the same
04/22/10Methods of preventing and treating rsv infections and related conditions
04/22/10Methods for cultivating cells, propagating and purifying viruses
03/11/10High affinity antibodies against hmgb1 and methods of use thereof
03/11/10Methods and compositions for increasing replication capacity of an influenza virus
02/04/10Recombinant rsv virus expression systems and vaccines
02/04/10Methods of administering/dosing anti-rsv antibodies for prophylaxis and treatment
12/24/09Refrigerator-temperature stable influenza vaccine compositions
12/03/09Humanization of antibodies
12/03/09Multi plasmid system for the production of influenza virus
12/03/09Recombinant human cytomegalovirus and vaccines comprising heterologous antigens
Social Network Patent Pack
11/19/09Nucleic acids encoding respiratory syncytial virus subgroup b strain 9320
11/05/09Recombinant rsv virus expression systems and vaccines
10/22/09Recombinant parainfluenza virus expression systems and vaccines comprising heterologous antigens derived from respiratory syncytial virus
10/01/09Methods of producing influenza vaccine compositions
08/20/09Multi plasmid system for the production of influenza virus
07/09/09Recombinant rsv virus expression systems and vaccines
07/09/09Multi plasmid system for the production of influenza virus
07/09/09Influenza hemagglutinin and neuraminidase variants
07/09/09Influenza hemagglutinin and neuraminidase variants
06/18/09Multispecific epitope binding proteins and uses thereof
05/07/09Functional mutations in respiratory syncytial virus
04/23/09Human-murine chimeric antibodies against respiratory syncytial virus
12/12/13Regimens for treatments using anti-igf antibodies







ARCHIVE: New 2017 2016 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Medimmune Llc in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Medimmune Llc with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###




';